BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

346 related articles for article (PubMed ID: 16763820)

  • 1. Comparison of the pharmacokinetics of 68Ga-DOTATOC and [18F]FDG in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki S; Strauss LG; Georgoulias V; Eisenhut M; Haberkorn U; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2006 Oct; 33(10):1115-22. PubMed ID: 16763820
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of the pharmacokinetics of 68Ga-DOTATOC in patients with metastatic neuroendocrine tumours scheduled for 90Y-DOTATOC therapy.
    Koukouraki S; Strauss LG; Georgoulias V; Schuhmacher J; Haberkorn U; Karkavitsas N; Dimitrakopoulou-Strauss A
    Eur J Nucl Med Mol Imaging; 2006 Apr; 33(4):460-6. PubMed ID: 16437218
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Quantitative assessment of SSTR2 expression in patients with non-small cell lung cancer using(68)Ga-DOTATOC PET and comparison with (18)F-FDG PET.
    Dimitrakopoulou-Strauss A; Georgoulias V; Eisenhut M; Herth F; Koukouraki S; Mäcke HR; Haberkorn U; Strauss LG
    Eur J Nucl Med Mol Imaging; 2006 Jul; 33(7):823-30. PubMed ID: 16570185
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Quantitative and qualitative intrapatient comparison of 68Ga-DOTATOC and 68Ga-DOTATATE: net uptake rate for accurate quantification.
    Velikyan I; Sundin A; Sörensen J; Lubberink M; Sandström M; Garske-Román U; Lundqvist H; Granberg D; Eriksson B
    J Nucl Med; 2014 Feb; 55(2):204-10. PubMed ID: 24379222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dynamic 68Ga-DOTATOC PET/CT and static image in NET patients. Correlation of parameters during PRRT.
    Van Binnebeek S; Koole M; Terwinghe C; Baete K; Vanbilloen B; Haustermans K; Clement PM; Bogaerts K; Verbruggen A; Nackaerts K; Van Cutsem E; Verslype C; Mottaghy FM; Deroose CM
    Nuklearmedizin; 2016 Jun; 55(3):104-14. PubMed ID: 27056060
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 68Ga-labeled bombesin studies in patients with gastrointestinal stromal tumors: comparison with 18F-FDG.
    Dimitrakopoulou-Strauss A; Hohenberger P; Haberkorn U; Mäcke HR; Eisenhut M; Strauss LG
    J Nucl Med; 2007 Aug; 48(8):1245-50. PubMed ID: 17631559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Parametric Net Influx Rate Images of
    Ilan E; Sandström M; Velikyan I; Sundin A; Eriksson B; Lubberink M
    J Nucl Med; 2017 May; 58(5):744-749. PubMed ID: 27789716
    [No Abstract]   [Full Text] [Related]  

  • 8. 68Ga-DOTATOC and 18F-FDG PET/CT for identifying the primary lesions of suspected and metastatic neuroendocrine tumors: A prospective study in Taiwan.
    Chen SH; Chang YC; Hwang TL; Chen JS; Chou WC; Hsieh CH; Yeh TS; Hsu JT; Yeh CN; Tseng JH; Chen TC; Yen TC
    J Formos Med Assoc; 2018 Jun; 117(6):480-487. PubMed ID: 28735662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A comparison of (111)In-DOTATOC and (111)In-DOTATATE: biodistribution and dosimetry in the same patients with metastatic neuroendocrine tumours.
    Forrer F; Uusijärvi H; Waldherr C; Cremonesi M; Bernhardt P; Mueller-Brand J; Maecke HR
    Eur J Nucl Med Mol Imaging; 2004 Sep; 31(9):1257-62. PubMed ID: 15197500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic Value of
    Zhang J; Liu Q; Singh A; Schuchardt C; Kulkarni HR; Baum RP
    J Nucl Med; 2020 Nov; 61(11):1560-1569. PubMed ID: 32169914
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo binding of [68Ga]-DOTATOC to somatostatin receptors in neuroendocrine tumours--impact of peptide mass.
    Velikyan I; Sundin A; Eriksson B; Lundqvist H; Sörensen J; Bergström M; Långström B
    Nucl Med Biol; 2010 Apr; 37(3):265-75. PubMed ID: 20346866
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Multicenter comparison of 18F-FDG and 68Ga-DOTA-peptide PET/CT for pulmonary carcinoid.
    Lococo F; Perotti G; Cardillo G; De Waure C; Filice A; Graziano P; Rossi G; Sgarbi G; Stefanelli A; Giordano A; Granone P; Rindi G; Versari A; Rufini V
    Clin Nucl Med; 2015 Mar; 40(3):e183-9. PubMed ID: 25608152
    [TBL] [Abstract][Full Text] [Related]  

  • 13. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
    Sampathirao N; Basu S
    J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
    [TBL] [Abstract][Full Text] [Related]  

  • 14. 68Ga-DOTATOC and FDG PET Imaging of Preclinical Neuroblastoma Models.
    Provost C; Prignon A; Cazes A; Combaret V; Delattre O; Janoueix-Lerosey I; Montravers F; Talbot JN
    Anticancer Res; 2016 Sep; 36(9):4459-66. PubMed ID: 27630282
    [TBL] [Abstract][Full Text] [Related]  

  • 15. 68Ga-DOTA-Tyr3-octreotide PET for assessing response to somatostatin-receptor-mediated radionuclide therapy.
    Gabriel M; Oberauer A; Dobrozemsky G; Decristoforo C; Putzer D; Kendler D; Uprimny C; Kovacs P; Bale R; Virgolini IJ
    J Nucl Med; 2009 Sep; 50(9):1427-34. PubMed ID: 19690033
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Quantitative, dynamic 18F-FDG-PET for the evaluation of soft tissue sarcomas: relation to differential diagnosis, tumor grading and prediction of prognosis.
    Okazumi S; Dimitrakopoulou-Strauss A; Schwarzbach MH; Strauss LG
    Hell J Nucl Med; 2009; 12(3):223-8. PubMed ID: 19936332
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prognostic aspects of 18F-FDG PET kinetics in patients with metastatic colorectal carcinoma receiving FOLFOX chemotherapy.
    Dimitrakopoulou-Strauss A; Strauss LG; Burger C; Rühl A; Irngartinger G; Stremmel W; Rudi J
    J Nucl Med; 2004 Sep; 45(9):1480-7. PubMed ID: 15347714
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dual-Tracer (68Ga-DOTATOC and 18F-FDG-)-PET/CT Scan and G1-G2 Nonfunctioning Pancreatic Neuroendocrine Tumors: A Single-Center Retrospective Evaluation of 124 Nonmetastatic Resected Cases.
    Paiella S; Landoni L; Tebaldi S; Zuffante M; Salgarello M; Cingarlini S; D'Onofrio M; Parisi A; Deiro G; Manfrin E; Bianchi B; Montagnini G; Crinò SF; Bassi C; Salvia R
    Neuroendocrinology; 2022; 112(2):143-152. PubMed ID: 33508821
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual tracer 68Ga-DOTATOC and 18F-FDG PET/computed tomography radiomics in pancreatic neuroendocrine neoplasms: an endearing tool for preoperative risk assessment.
    Mapelli P; Partelli S; Salgarello M; Doraku J; Pasetto S; Rancoita PMV; Muffatti F; Bettinardi V; Presotto L; Andreasi V; Gianolli L; Picchio M; Falconi M
    Nucl Med Commun; 2020 Sep; 41(9):896-905. PubMed ID: 32796478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Focal uptake of 68Ga-DOTATOC in the pancreas: pathological or physiological correlate in patients with neuroendocrine tumours?
    Al-Ibraheem A; Bundschuh RA; Notni J; Buck A; Winter A; Wester HJ; Schwaiger M; Scheidhauer K
    Eur J Nucl Med Mol Imaging; 2011 Nov; 38(11):2005-13. PubMed ID: 21792572
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.